This discovery opens up new therapeutic possibilities, as the tested small molecule inhibitors of IGF2BP3 efficiently decreased FMRpolyG levels, which is a driver of FXTAS pathogenesis. The gene discussed is IGF2BP3; the disease is fragile X-associated tremor/ataxia syndrome.